Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients | Zendy

Christoph Kreer | Zendy; Matthias Zehner | Zendy; Timm Weber | Zendy; Meryem S. Ercanoglu | Zendy; Lutz Gieselmann | Zendy; Cornelius Rohde | Zendy; Sandro Halwe | Zendy; Michael Korenkov | Zendy; Philipp Schommers | Zendy; Kanika Vanshylla | Zendy; Veronica Di Cristanziano | Zendy; Hanna Janicki | Zendy; Reinhild Brinker | Zendy; Artem Ashurov | Zendy; Verena Krähling | Zendy; Alexandra Kupke | Zendy; Hadas CohenDvashi | Zendy; Manuel Koch | Zendy; Jan Mathis Eckert | Zendy; Simone Lederer | Zendy; Nico Pfeifer | Zendy; Timo Wolf | Zendy; Maria J. G. T. Vehreschild | Zendy; ClemensMartin Wendtner | Zendy; Ron Diskin | Zendy; Henning Gruell | Zendy; Stephan Becker | Zendy; Florian Klein | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients

Author(s) -

Christoph Kreer,

Matthias Zehner,

Timm Weber,

Meryem S. Ercanoglu,

Lutz Gieselmann,

Cornelius Rohde,

Sandro Halwe,

Michael Korenkov,

Philipp Schommers,

Kanika Vanshylla,

Veronica Di Cristanziano,

Hanna Janicki,

Reinhild Brinker,

Artem Ashurov,

Verena Krähling,

Alexandra Kupke,

Hadas CohenDvashi,

Manuel Koch,

Jan Mathis Eckert,

Simone Lederer,

Nico Pfeifer,

Timo Wolf,

Maria J. G. T. Vehreschild,

ClemensMartin Wendtner,

Ron Diskin,

Henning Gruell,

Stephan Becker,

Florian Klein

Publication year - 2020

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2020.06.044

Subject(s) - biology , covid-19 , virology , antibody , germline , isolation (microbiology) , neutralizing antibody , genetics , gene , outbreak , bioinformatics , infectious disease (medical specialty) , disease , medicine , pathology

The SARS-CoV-2 pandemic has unprecedented implications for public health, social life, and the world economy. Because approved drugs and vaccines are limited or not available, new options for COVID-19 treatment and prevention are in high demand. To identify SARS-CoV-2-neutralizing antibodies, we analyzed the antibody response of 12 COVID-19 patients from 8 to 69 days after diagnosis. By screening 4,313 SARS-CoV-2-reactive B cells, we isolated 255 antibodies from different time points as early as 8 days after diagnosis. Of these, 28 potently neutralized authentic SARS-CoV-2 with IC 100 as low as 0.04 μg/mL, showing a broad spectrum of variable (V) genes and low levels of somatic mutations. Interestingly, potential precursor sequences were identified in naive B cell repertoires from 48 healthy individuals who were sampled before the COVID-19 pandemic. Our results demonstrate that SARS-CoV-2-neutralizing antibodies are readily generated from a diverse pool of precursors, fostering hope for rapid induction of a protective immune response upon vaccination.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research